rs1234314 — TNFSF4
Intronic variant in TNFSF4 that reduces OX40 ligand promoter activity and is independently associated with susceptibility to systemic sclerosis and systemic lupus erythematosus
Details
- Gene
- TNFSF4
- Chromosome
- 1
- Risk allele
- G
- Clinical
- Risk Factor
- Evidence
- Moderate
Population Frequency
See your personal result for TNFSF4
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
TNFSF4 rs1234314 — The OX40 Ligand Variant That Quiets T Cell Co-stimulation
The immune system's response to tissue injury, infection, or self-antigens depends
on a system of activating and restraining signals. Among the activating signals, the
OX40–OX40L axis11 OX40–OX40L axis
OX40 (CD134) is expressed on activated T cells; OX40L (CD252),
encoded by TNFSF4, is expressed on antigen-presenting cells and delivers a survival
and proliferation signal that amplifies the T cell response
is one of the most potent co-stimulatory pathways in adaptive immunity. rs1234314 is
an intronic variant in TNFSF4 that reduces the gene's promoter activity, altering the
quantity of OX40L produced. It provides an independent association signal at the
TNFSF4 locus, separate from the well-characterized upstream risk haplotype tagged by
rs7514229 and rs2205960, and has been associated with susceptibility to systemic
sclerosis (scleroderma) and systemic lupus erythematosus across multiple cohorts.
The Mechanism
rs1234314 sits within an intron of TNFSF4 on chromosome 1 (GRCh38 chr1:173208253),
a gene transcribed from the minus strand. The plus-strand notation is C>G, with C as
the GRCh38 reference allele. A 2023 promoter-reporter study22 2023 promoter-reporter study
Chen et al. J Clin Med
2023 (PMID 36983159) — dual-luciferase assay; >10 independent experiments per variant;
one-way ANOVA p=0.003 demonstrated that
the G allele drives approximately 68% less transcriptional activity than the C allele
in promoter-reporter constructs — the G-allele construct produced only 0.32 ± 0.09
times the relative light units of the C-allele reference. This functional effect
establishes rs1234314 as a regulatory variant that modulates TNFSF4 expression, not
merely a passive tag for a nearby causal variant.
The consequence of reduced OX40L expression is not straightforwardly protective.
OX40L is required not only for effector T cell activation but also for the
differentiation and persistence of regulatory T cells (Tregs33 Tregs
Regulatory T cells
that suppress immune activation and maintain tolerance to self-antigens; their function
depends partly on OX40 signaling for maintenance in inflamed tissues).
Insufficient OX40 co-stimulation may selectively impair Treg maintenance in inflamed
tissue, while early effector T cell responses proceed through other co-stimulatory
pathways — a net dysregulation that promotes autoimmune chronicity.
The Evidence
The first identification of rs1234314 as a risk locus came from a 2010 case-control
study of systemic sclerosis44 2010 case-control
study of systemic sclerosis
Gourh et al. Ann Rheum Dis 2010 (PMID 19778912) —
1,059 SSc patients, 698 controls; nine TNFSF4 SNPs tested; FDR-corrected
p=0.019 in North American patients.
The minor (G) allele at rs1234314 conferred an odds ratio of 1.20 (95% CI 1.04–1.40)
for SSc susceptibility. This was replicated55 replicated
Bossini-Castillo et al. Ann Rheum Dis
2011 (PMID 21187296) — 3,014 SSc cases and 3,125 controls across Germany, Spain,
The Netherlands, Italy, France, UK, Czech Republic, and Norway; multi-cohort
meta-analysis in the largest European
SSc genetics cohort assembled at that time (n=6,139), yielding an overall OR of 1.15
(95% CI 1.02–1.31), with stronger effects in limited cutaneous SSc (lcSSc; OR 1.22)
and anti-centromere antibody (ACA)-positive patients (OR 1.23).
For systemic lupus erythematosus, a trans-ancestral fine-mapping study66 trans-ancestral fine-mapping study
Manku et al.
Ann Rheum Dis 2013 (PMID 23874208) — 17,900 SLE and control subjects spanning
Amerindian/Hispanic, African-American, European, and East Asian ancestries; conditional
regression analyses identified rs1234314-C
as an independent non-risk signal at the TNFSF4 locus — meaning the C allele is
associated with protection, and the G allele carries SLE risk as a signal independent
of the primary rs2205960-T risk haplotype. A Taiwanese case-control study77 Taiwanese case-control study
Chen et al.
Front Immunol 2022 (PMID 36189300)
corroborated this direction: rs1234314 genotype distribution differed significantly
between SLE cases and controls (CC vs. CG vs. GG: p=0.005), with GG vs. CC comparison
reaching p=0.004.
Practical Implications
The TNFSF4 locus, via multiple independent signals including rs1234314, is one of the most consistently replicated genetic associations for both scleroderma and lupus. Carriers of the G allele have a modestly elevated background risk for these conditions — approximately 15–20% higher odds per the SSc replication data. The clinical translation is not treatment of genetic risk, but informed monitoring: recognizing early features of these conditions that warrant specialist evaluation.
Systemic sclerosis (scleroderma) often begins with Raynaud's phenomenon88 Raynaud's phenomenon
Episodic
vasospasm causing fingers and toes to turn white or blue in response to cold or stress;
present in >95% of SSc patients, often preceding skin and organ involvement by years
— abnormal cold sensitivity — and progresses to skin thickening, internal organ fibrosis,
and vascular disease. Early detection matters because immunosuppressive treatment is most
effective before irreversible fibrosis occurs.
Interactions
rs1234314 provides an independent genetic signal at the TNFSF4 locus that is separate from the upstream risk haplotype tagged by rs7514229 and rs2205960. The trans-ancestral fine-mapping study (PMID 23874208) demonstrated that conditional regression analysis delineates the primary risk signal to rs2205960-T and the independent signal to rs1234314-G, confirming these two signals coexist without full mutual explanation. A carrier of both the rs7514229-T (upstream haplotype) and rs1234314-G alleles would carry two independent TNFSF4 risk signals, a combination worth noting in the context of autoimmune risk assessment.
Genotype Interpretations
What each possible genotype means for this variant:
Common homozygous reference — full OX40L promoter activity, no TNFSF4 G allele
You carry two copies of the C reference allele at rs1234314. The C allele maintains full TNFSF4 promoter activity and is the most common genotype globally, present in approximately 36% of people. European allele frequency for C is about 58%, making CC common in European-ancestry populations. You do not carry the G allele that substantially reduces TNFSF4 transcription and is independently associated with systemic sclerosis and lupus susceptibility in published cohort studies.
One G allele — heterozygous, partial reduction in TNFSF4 promoter activity
The G allele at rs1234314 reduces TNFSF4 promoter activity to approximately 32% of the C-allele level in dual-luciferase reporter assays (Chen et al. 2023, PMID 36983159, p=0.003 vs. C reference). TNFSF4 encodes OX40L (CD252), a co-stimulatory ligand for the OX40 receptor on activated T cells. Reduced OX40L expression may impair regulatory T cell (Treg) maintenance in inflamed tissues while leaving early effector responses relatively intact through other co-stimulatory pathways, creating a net dysregulation that may favor autoimmune chronicity.
The SSc association at rs1234314 was established in North American populations (Gourh et al. 2010, PMID 19778912; OR 1.20) and replicated across 8 European cohorts totaling 6,139 participants (Bossini-Castillo et al. 2011, PMID 21187296; OR 1.15 overall). The SLE association was formally characterized as an independent signal at the TNFSF4 locus in a trans-ancestral fine-mapping study (Manku et al. 2013, PMID 23874208; rs1234314-C identified as the non-risk allele, implying G carries the risk).
Homozygous G allele — maximal reduction in TNFSF4 promoter activity, highest risk genotype
OX40L (encoded by TNFSF4) is a co-stimulatory ligand on antigen-presenting cells that engages OX40 (CD134) on activated T cells, sustaining T cell survival, promoting Th2 cytokine output, and supporting B cell differentiation in germinal centers. Reduced OX40L does not simply mean less T cell activation — it also impairs the survival of regulatory T cells (Tregs) in peripheral inflamed tissues, where OX40 signaling is required for Treg persistence. The net effect of low TNFSF4 activity may be paradoxically pro-inflammatory through impaired peripheral tolerance rather than reduced effector T cell priming.
The SSc association evidence for rs1234314 includes a North American discovery (Gourh et al. 2010, n=1,757, OR 1.20, p_FDR=0.019) replicated in a pan-European cohort (Bossini-Castillo et al. 2011, n=6,139, OR 1.15), with the strongest effects in limited cutaneous SSc (lcSSc) and anti-centromere antibody (ACA) positive patients (OR 1.23). The lcSSc subtype is characterized by skin fibrosis distal to the elbows/knees, pulmonary arterial hypertension risk, and ACA positivity — a clinically distinct phenotype with a specific monitoring protocol.
For SLE, a trans-ancestral fine-mapping study (Manku et al. 2013) established rs1234314-G as an independent risk signal separate from the primary rs2205960-T risk haplotype, with functional validation of this independent signal in 17,900 subjects across four ancestries. The Taiwanese case-control study (Chen et al. 2022, PMID 36189300) found GG vs. CC comparison p=0.004, confirming the risk directionality.